Neuland Laboratories Ltd (NEULANDLAB) — Announcement | 15 September 2026

15 September 2026 · BSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

First commercial peptide module operational, capacity expansion underway

🔮 What's Next

Module two planned with up to 18,000L capacity; investment aligned with new customer requirements

💡 Investor Takeaway

This expansion strengthens Neuland's position as a leading peptide CDMO and supports long-term revenue growth.

Neuland Laboratories announced that its first commercial peptide manufacturing module is now operational, adding 7000L reactor capacity and 750L solid-phase synthesis, with plans to accelerate a second module to 18,000L capacity and expand into oncology, supporting growth in complex peptide APIs and commercial contracts.

📄 View Original Announcement (PDF)

📊 Stock Analysis — NEULANDLAB ✨ Ask AI About This

About Neuland Laboratories Ltd (NEULANDLAB)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹27,498.49 CrP/E: 55.2ROE: 26.6%ROCE: 33.6%Div Yield: 0.16%

View full NEULANDLAB stock details →

📡 Get AI alerts when NEULANDLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track NEULANDLAB — Free

💡 Ask AI about this filing

"How will the new capacity affect Neuland's revenue growth?""What is the expected timeline for module two completion?""How does the oncology focus impact future margins?"

Ask AI Free →

📊 More NEULANDLAB filings

Announcement — 25 September 2026Neuland Laboratories has closed its insider trading window effective October 1, 2026, until 48 hours...
🔴 Announcement — 16 September 2026Neuland Laboratories announced its management will attend the Goldman Sachs Global Healthcare CDMO D...
🔴 Announcement — 9 September 2026Neuland Laboratories announced its management will attend three upcoming investor meetings in Septem...
🟡 Board Meeting — 7 September 2026Neuland Laboratories announced on September 7, 2026, that its board approved ₹126 crores capital exp...
🔴 Announcement — 25 August 2026Neuland Laboratories Limited announced that CRISIL has reaffirmed its long-term rating at CRISIL A+ ...

See all NEULANDLAB filings →

🔥 Also filed on 15 September 2026

MUTHOOTMFMuthoot Microfin LtdCorporate Action JUBLFOODJubilant Foodworks LtdAnnouncement 523467Jai Mata Glass LtdOffer Document BLUECLOUDSBlue Cloud Softech Solutions LtdAnnouncement FREDUNFredun Pharmaceuticals LtdAnnouncement IZMOIZMO LtdAnnouncement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when NEULANDLAB files new disclosures

Track NEULANDLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.